Autosomal Dominant Polycystic Kidney Disease Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight

DelveInsight's "Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Autosomal Dominant Polycystic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Autosomal Dominant Polycystic Kidney Disease Market Forecast
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Autosomal Dominant Polycystic Kidney Disease Market Report:
• The Autosomal Dominant Polycystic Kidney Disease market size was valued approximately USD 1,476 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In April 2025, Rege Nephro is advancing a Phase 2 clinical trial in Japan to assess Tamibarotene (RN-014), a retinoic acid receptor agonist, for treating autosomal dominant polycystic kidney disease (ADPKD). Upon demonstrating its efficacy and safety in Japan, the company intends to initiate clinical trials in the United States. Tamibarotene was previously studied by Syros Pharmaceuticals in a Phase 3 trial for conditions including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
• In March 2025, Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company dedicated to developing innovative microRNA-targeting therapies, has announced positive topline results from all participants in the fourth cohort of its Phase 1b multiple ascending dose (MAD) study of farabursen for the treatment of autosomal dominant polycystic kidney disease (ADPKD). This Phase 1b MAD trial is a randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics (PK/PD) of farabursen in adult ADPKD patients.
• In October 2024, Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company dedicated to discovering and developing innovative medicines targeting microRNAs, announced today that it has completed enrollment of 26 patients in the fourth cohort of the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
• In April 2024, Eloxx Pharmaceuticals made significant progress in developing ELX-02 for treating Alport syndrome with Nonsense Mutations (NMAS). Furthermore, through its global licensing agreement with Almirall announced in March, the company has initiated the development of ZKN-013 for treating Recessive Dystrophic Epidermolysis Bullosa (RDDEB) and Familial Adenomatous Polyposis (FAP) patients with nonsense mutations. A recent publication on Autosomal Dominant Polycystic Kidney Disease (ADPKD) highlights the potential of ELX-02 in treating all rare genetic kidney diseases with nonsense mutations in the disease-causing genes.
• In 2023, the US market was valued at around USD 889.8 million. This figure is expected to shift with the introduction of emerging therapies throughout the forecast period (2024-2034).
• In 2023, the combined market size of EU4 and the UK was approximately USD 7,395 million, representing nearly 39.4% of the total 7MM market.
• In the EU4 and the UK, the UK had the largest autosomal dominant polycystic kidney disease market size at around USD 72.5 million, followed by France with approximately USD 65.6 million and Spain with USD 29.4 million. These figures are projected to shift by 2034.
• In 2023, Japan represented about 26% of the total Autosomal Dominant Polycystic Kidney Disease market across the 7MM. These proportions are expected to shift by 2034.
• According to DelveInsight's analysis, the total diagnosed prevalent cases of autosomal dominant polycystic kidney disease in the 7MM were approximately 194,251 in 2023. This number is expected to change during the forecast period from 2024 to 2034.
• In 2023, the US reported approximately 144,697 diagnosed prevalent cases of autosomal dominant polycystic kidney disease.
• In 2023, the UK reported the highest number of autosomal dominant polycystic kidney disease diagnosed prevalent cases among the EU4 and the UK, with approximately 68,138 cases, followed by France with 61,676 cases. Italy had the lowest, with nearly 16,476 cases.
• Key Autosomal Dominant Polycystic Kidney Disease Companies: Otsuka America Pharmaceuticals, Vertex Pharmaceuticals, Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, ReataPharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others
• Key Autosomal Dominant Polycystic Kidney Disease Therapies: JYNARQUE/ JINARC/SAMSCA (tolvaptan), VX-407, Bosutinib, Tolvaptan, Lixivaptan, Everolimus, OPC-41061, Rapamune, XRx-008, Bardoxolonemethyl, Tesevatinib/KD019, GLPG2737, JNJ-0237/AT-20494, RGLS8429, and others
• The ADPKD epidemiology based on mutation-specific cases analyzed that the mutation-specific distribution of the disease suggests a higher prevalence of ADPKD due to mutation in PKD1 gene than in PKD2 gene
• The Autosomal Dominant Polycystic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Autosomal Dominant Polycystic Kidney Disease pipeline products will significantly revolutionize the Autosomal Dominant Polycystic Kidney Disease market dynamics.

Autosomal Dominant Polycystic Kidney Disease Overview
Autosomal Dominant Polycystic Kidney Disease is a genetic disorder characterized by the development of numerous fluid-filled cysts primarily within the kidneys. It is one of the most common inherited kidney disorders.

Get a Free sample for the Autosomal Dominant Polycystic Kidney Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Autosomal Dominant Polycystic Kidney Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Autosomal Dominant Polycystic Kidney Disease Epidemiology Segmentation:
The Autosomal Dominant Polycystic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Autosomal Dominant Polycystic Kidney Disease
• Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease by severity
• Gender-specific Prevalence of Autosomal Dominant Polycystic Kidney Disease
• Diagnosed Cases of Episodic and Chronic Autosomal Dominant Polycystic Kidney Disease

Download the report to understand which factors are driving Autosomal Dominant Polycystic Kidney Disease epidemiology trends @ Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Autosomal Dominant Polycystic Kidney Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autosomal Dominant Polycystic Kidney Disease market or expected to get launched during the study period. The analysis covers Autosomal Dominant Polycystic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Autosomal Dominant Polycystic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Autosomal Dominant Polycystic Kidney Disease Therapies and Key Companies
• JYNARQUE/ JINARC/SAMSCA (tolvaptan): Otsuka America Pharmaceuticals
• VX-407: Vertex Pharmaceuticals
• Bosutinib: Pfizer
• Tolvaptan: Otsuka Pharma
• Lixivaptan: Palladio Biosciences
• Everolimus: Novartis Pharma
• OPC-41061: Otsuka Pharma
• Rapamune: Pfizer
• XRx-008: XORTX Therapeutic
• Bardoxolonemethyl: ReataPharmaceuticals/ Kyowa Kirin
• Tesevatinib/KD019: Sanofi
• GLPG2737: Galapagos NV
• JNJ-0237/AT-20494: Janssen Pharmaceuticals
• RGLS8429: RegulusTherapeutics

Discover more about therapies set to grab major Autosomal Dominant Polycystic Kidney Disease market share @ Autosomal Dominant Polycystic Kidney Disease Treatment Landscape
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Autosomal Dominant Polycystic Kidney Disease Market Drivers
• Technological advances in diagnostic procedures due to an increasing focus on early diagnosis has reduced undiagnosed cases, thus persistent rising cases of diagnosed ADPKD offer opportunities to companies to launch new therapies in the market.
• Advances are being made in unravelling the genetic origins of ADPKD, in non-invasive monitoring and in predicting disease progression that will help in better disease management

Autosomal Dominant Polycystic Kidney Disease Market Opportunities
• Pre-symptomatic diagnosis and their application in the care and management of individuals at risk for ADPKD.
• Identification of biomarkers for early detection of ADPKD patients at high risk for progression will help better manage ADPKD patients and prevent their progression.

Scope of the Autosomal Dominant Polycystic Kidney Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Autosomal Dominant Polycystic Kidney Disease Companies: Otsuka America Pharmaceuticals, Vertex Pharmaceuticals, Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, ReataPharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others
• Key Autosomal Dominant Polycystic Kidney Disease Therapies: JYNARQUE/ JINARC/SAMSCA (tolvaptan), VX-407, Bosutinib, Tolvaptan, Lixivaptan, Everolimus, OPC-41061, Rapamune, XRx-008, Bardoxolonemethyl, Tesevatinib/KD019, GLPG2737, JNJ-0237/AT-20494, RGLS8429, and others
• Autosomal Dominant Polycystic Kidney Disease Therapeutic Assessment: Autosomal Dominant Polycystic Kidney Disease current marketed and Autosomal Dominant Polycystic Kidney Disease emerging therapies
• Autosomal Dominant Polycystic Kidney Disease Market Dynamics: Autosomal Dominant Polycystic Kidney Disease market drivers and Autosomal Dominant Polycystic Kidney Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Autosomal Dominant Polycystic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Autosomal Dominant Polycystic Kidney Disease Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.